Updated:
Astra Zeneca CICC Healthcare Venture Capital Fund
The fund represents a rare collaboration between a global pharmaceutical company and a leading Chinese investment bank, formalized through a joint venture...
Astra Zeneca CICC Healthcare Venture Capital Fund
The fund represents a rare collaboration between a global pharmaceutical company and a leading Chinese investment bank, formalized through a joint venture structure. While the exact founding year remains unconfirmed in public record, the partnership was disclosed around 2020 as part of AstraZeneca's broader China strategy under CEO Pascal Soriot. CICC contributes capital markets and regulatory navigation expertise within China, while AstraZeneca provides scientific validation and pipeline insight. The strategy spans therapeutics, medical devices, diagnostics, and digital health. The fund typically invests at Series A through growth equity stages, favoring companies with clinical data and a pathway to China's National Medical Products Administration (NMPA) approval, where CICC's regulatory relationships can accelerate market entry. This dual-anchor model—pharma R&D credibility plus Chinese financial infrastructure—differentiates the fund from pure financial VCs. Geographic focus concentrates on US- and China-headquartered companies, with Singapore serving as a secondary hub for Southeast Asian deal flow. The fund operates through a team drawn from AstraZeneca's business development unit and CICC's private equity division. Its presence across Menlo Park, Shanghai, Hong Kong, Wuxi, and Singapore reflects the operational reality of a bi-lateral investment mandate. Adjacent activities remain unclear; public record does not currently detail philanthropic vehicles or club deal participation associated with this entity. The structural differentiator is the fund's embedded relationship with a top-10 global pharmaceutical company as a strategic limited partner and validation engine, rather than a passive financial backer. No other healthcare VC fund publicly claims co-ownership by a multinational pharma company and a Chinese investment bank, which positions the vehicle uniquely for FDA-to-NMPA bridge financings.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Menlo Park
Corporate office
Menlo Park, California, United States
Additional offices
Shanghai, China · Hong Kong · Wuxi, China · Singapore
Sector focus
Frequently asked questions
Who runs investment decisions at the Astra Zeneca CICC Healthcare Venture Capital Fund?
Investment decisions are made through a joint committee comprising professionals from AstraZeneca's business development and venture arms, alongside CICC's private equity team. Individual decision-makers' names are not listed in a centralized public source; the structure suggests a shared governance model rather than a single CIO-led process (per public record).
What investment stages does the fund typically target?
The fund targets Series A through growth equity rounds, focusing on companies with early clinical data or regulatory submissions. This stage preference aligns with AstraZeneca's ability to provide scientific diligence and CICC's capacity to support later-stage capital needs and Chinese market entry (per public record).
How is the fund structurally different from a typical healthcare VC?
Unlike pure financial sponsors, the fund is co-owned by AstraZeneca—a global pharmaceutical company—and CICC, a Chinese investment bank. This gives it a dual mandate: financial returns plus strategic value creation through AstraZeneca's clinical validation resources and CICC's Chinese regulatory and distribution network.
How is the fund related to AstraZeneca's broader venture activities?
This fund is distinct from AstraZeneca's internal corporate venture arm, which invests off the parent balance sheet. The CICC joint venture operates as an independent pooled fund with external limited partners, though AstraZeneca retains disproportionate strategic influence and deal-flow sourcing advantages through the partnership (per public record).
What is the fund's known posture on co-investments alongside external GPs?
Public record does not clarify whether the fund routinely co-invests alongside external GPs. Given the strategic nature of the CICC partnership and the limited public disclosure, co-investment activity is likely evaluated on a deal-by-deal basis, particularly for syndications crossing US and China regulatory jurisdictions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: